Glucagon-like peptide-1 receptor agonists

Results 261 to 270 of about 106,022 (294)

Some of the next articles are maybe not open access.

Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study

Diabetes, obesity and metabolism
We aimed to investigate the long‐term impact of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on thyroid function, cardiovascular health, renal outcomes and adverse events in individuals with obesity and without type 2 diabetes (T2D).
Yu-Nan Huang +7 more
semanticscholar +1 more source

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease

Alimentary Pharmacology and Therapeutics
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) show anti‐inflammatory properties.
Aakash Desai +6 more
semanticscholar +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Youth Obesity

JAMA Pediatrics
This Viewpoint discusses the use of glucagon-like peptide-1 receptor agonist treatments for weight management in youth.
Emma K, Edmondson, Rachana D, Shah, Emily F, Gregory +2 more
openaire +2 more sources

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

Circulation, 2022
, Bernard Zinman, Ahmed Shaman
exaly

Glucagon-Like Peptide-1 Receptor Agonists and Cancer